Companies Profiled in Insulin Delivery Devices Market are Insulet Corporation, Eli Lilly and Company, BD, Roche, Novo Nordisk

The insulin delivery devices market faces some peculiar challenges which have been and will continue to be hindering growth during the forecast period. Factors such as high cost of insulin and insulin delivery devices, inconsistencies in adherence of insulin uptake and psychological resistances to self-injection due to needle-phobia are major roadblock in insulin delivery devices market growth. Low per capita diabetes expenditure, and lack of reimbursement and insurance coverage in emerging economies happen to be significant constraints in industry growth. During the forecast period, high cost of devices will result in slow and low adoption rates, especially in resource poor economies.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/1649

Insulin pumps market was valued more than USD 1.9 billion in 2017 and is forecast to grow at a CAGR of over 7.5% from 2018 to 2024. The need for better diabetes management will drive demand for the insulin pumps during the forecast period. Minimally invasive nature of pumps will increasingly attract more consumers over the coming years, especially in industrialized nation; however, their cost will prove to be a major restraining factor for the business growth.

Insulin pen is most popular in insulin delivery devices gamut; in fact, its market valued at over USD 6.5 billion in 2017. Being available since late 1980’s, its business has grown into a multi-billion-dollar market and is expected to lead the industry during the forecast period. Insulin pen adoption is most likely to grow in developing nations having more than average diabetes patient in low income group.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
1. Roche
2. Eli Lilly and Company
3. Medtronic
4. Novo Nordisk
5. Sanofi
6. BD
7. Wockhardt Ltd.
8. Insulet Corporation
9. Ypsomed AG

The demand for injection free minimally invasive systems will drive pumps’ market growth over the forecast timeframe. Factors such as, ease of use, needleless insulin delivery and portability will result in rapid adoption of the same in coming 5-7 years. The insulin pumps market is forecast to grow with CAGR of over 7% during projection years.

UK insulin delivery devices market valued over USD 500 million in 2017 and is forecast to grow with a commanding CAGR during the projection years. Demand for insulin pens happens to be high across the nation; however, demand for pumps, which has been lesser popular devices, should rise significantly over the forecast timeframe.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/1649

U.S. insulin delivery devices market was valued at USD 5.0 billion in 2017 and accounted for regional share of more than 95% in 2017. Increasing diabetes prevalence coupled with rising disposable income level will drive market growth over the forecast period. Technological advances in insulin delivery devices along with favourable government initiatives to execute better diabetes management will further fuel industry growth.

Insulin Delivery Devices Market by Product
o Pumps
• Tubed
• Tubeless
o Pens
• Reusable
• Disposable
o Pen Needles
• Standard
• Safety

Global Market Insights Inc. is a global market research and management consulting company catering to leading corporations, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

Global Market Insights, Inc.
4 North Main Street
Selbyville, Delaware 19975 USA
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:sales@gminsights.com

This release was published on openPR.